OS-01

OS-01, also known as Peptide 14, Pep 14, or Decapeptide-52, is a synthetic peptide developed to investigate cellular senescence and age-related deterioration of human skin. It was identified through a phenotypic screening program designed to discover compounds that reduce senescence-associated changes in human skin cells. Research suggests that OS-01 modulates pathways involving protein phosphatase 2A (PP2A), cellular stress responses, and the senescence-associated secretory phenotype (SASP). Its proposed senomorphic activity makes it distinct from senolytic compounds that aim to eliminate senescent cells through programmed cell death.

Laboratory and ex-vivo human skin studies demonstrate reductions in selected senescence markers and changes in DNA-methylation-based biological-age measurements. Small human clinical studies of topical formulations containing OS-01 have reported improvements in skin barrier function, moisture retention, hydration, and selected cosmetic measurements. A randomized study involving older women also reported changes in circulating inflammatory biomarkers. However, these findings remain preliminary, and the effects of complete skincare formulations cannot always be attributed solely to the peptide. OS-01 is not an FDA-approved therapeutic drug, and no established human evidence supports injectable treatment for osteoporosis, bone regeneration, systemic longevity, or other internal medical conditions.

OS-01 is investigated primarily as a senomorphic peptide. Its proposed activity involves reducing the progression and inflammatory characteristics of cellular senescence, particularly within aging human skin. Its strongest mechanistic evidence involves PP2A-associated signaling, rather than direct activation of AMPK.

1. Cellular Senescence and Skin Aging

• Cellular senescence is a biological state in which cells stop dividing and undergo changes in metabolism, stress signaling, and gene expression.
• Senescent cells can accumulate in aging skin following ultraviolet exposure, repeated stress, DNA damage, and other insults.
• Some senescent cells release inflammatory mediators, proteases, and growth-related molecules collectively described as the senescence-associated secretory phenotype (SASP).
• These signals can influence surrounding fibroblasts, extracellular matrix organization, inflammation, and tissue maintenance.
• However, cellular senescence also has beneficial roles in normal wound healing and tumor suppression; it is not universally harmful.

2. Senomorphic Rather Than Senolytic Activity

• Senolytic interventions are designed to eliminate susceptible senescent cells.
• Senomorphic approaches aim to modify senescence-associated signaling or reduce harmful features without necessarily killing the cells.
• OS-01 was identified through screening for peptides that modify senescence-related changes.
• Experiments reported reduced accumulation of certain late-senescence cell populations and lower expression of several SASP-related genes.
• These findings support its classification as a senomorphic candidate, although cellular effects vary with the experimental model.

3. PP2A-Associated Signaling

• Protein phosphatase 2A (PP2A) is an enzyme complex involved in regulating phosphorylation-dependent cellular signals.
• Research on OS-01 identified changes in expression of the PP2A-associated gene PPP2R1A and levels of a PP2A structural subunit.
• Investigators also observed changes in AKT phosphorylation and signaling related to cell-cycle regulation.
• Experimental PP2A inhibition and gene-silencing studies supported a role for this pathway in OS-01's effects.
• The specific molecular binding interactions and complete downstream mechanism remain incompletely defined.
• It has not been established that OS-01 directly binds or activates AMPK as its principal target.

4. AKT, Cell-Cycle and DNA-Repair Responses

• AKT signaling influences metabolism, growth, stress adaptation, and cellular survival.
• OS-01-treated fibroblasts demonstrated changes in phosphorylated AKT, CDK2AP1, and genes involved in cell-cycle regulation.
• Single-cell analyses suggested that treatment reduced progression toward selected late-senescence states.
• Changes in DNA-repair-associated gene expression were also observed.
• These findings describe laboratory signaling responses rather than demonstrated repair of human DNA damage or prevention of cancer.

5. Senescence-Associated Secretory Phenotype

• SASP describes a mixture of cytokines, chemokines, proteases, and other factors released by some senescent cells.
• OS-01 experiments demonstrated reductions in selected SASP-related markers, including IL-6-associated and CXCL chemokine pathways.
• In skin models, expression of genes including CXCL8 and CDKN2A changed following treatment.
• These results support research into limiting damaging inflammatory communication between neighboring cells.
• They do not establish that topical OS-01 eliminates systemic chronic inflammation.

6. Skin Barrier Function

• The epidermal barrier helps prevent excessive water loss and limits exposure to environmental irritants.
• Aging skin may experience changes in barrier integrity, epidermal structure, and hydration.
• Laboratory models treated with OS-01 demonstrated improvements in selected measures of epidermal organization and keratinocyte-associated gene expression.
• Human topical studies subsequently reported improvements in transepidermal water loss (TEWL).
• Lower TEWL generally reflects improved water retention by the skin barrier, although it does not independently establish biological-age reversal.

7. Collagen and Extracellular Matrix Signaling

• Dermal fibroblasts produce collagen and other extracellular matrix components that support skin structure.
• Ex-vivo skin experiments demonstrated changes in expression of COL1A1, HAS2, MMP1, and other tissue-remodeling genes.
• These markers are involved in collagen production, hyaluronic acid biology, and extracellular matrix turnover.
• OS-01-treated tissue also demonstrated selected changes in epidermal thickness and histological appearance.
• However, changes in gene expression are not equivalent to clinically demonstrated increases in collagen density or permanent wrinkle reversal.

8. Experimental Skin Biological-Age Measurements

• DNA-methylation clocks estimate aspects of biological age from patterns of methylation across the genome.
• Researchers applied OS-01 to isolated human skin samples maintained under laboratory conditions.
• After five days, the MolClock algorithm estimated an average reduction in skin equivalent biological age of approximately 2.6 years.
• Other molecular clocks also identified changes consistent with a younger predicted skin profile.
• These findings were measured in ex-vivo tissue rather than through a clinical trial showing that living people became biologically younger.
• Changes in an aging-clock score do not independently demonstrate longer lifespan, disease prevention, or durable tissue rejuvenation.

9. Circulating Inflammatory Biomarkers

• A 2025 clinical study examined whether improvements in aging skin might influence circulating inflammation-related measurements.
• Participants receiving an OS-01-containing topical formulation demonstrated reductions in selected cytokines, including IL-8.
• The study also reported changes in IL-10, while certain inflammatory markers increased in the comparison group.
• These results are exploratory and require larger independent clinical confirmation.
• Changes in blood cytokines do not establish lower risk of cardiovascular disease, dementia, cancer, or other age-related conditions.

10. Absorption and Localized Activity

• In the 2025 older-adult study, researchers tested plasma for detectable OS-01 using mass spectrometry.
• The peptide was not detected at the measured time points under the analytical conditions used.
• This supports the possibility that the tested formulation acts primarily through local skin exposure.
• However, nondetection does not prove that systemic absorption is absolutely zero under every condition.
• The results do not establish the safety of injecting OS-01 or using it on extensively damaged skin.

11. What About AMPK, Autophagy and Mitochondrial Biogenesis?

• AMPK is a major cellular energy-sensing pathway with important effects on metabolism and stress adaptation.
• The small molecule O-304, also known as ATX-304, has been independently studied as an AMPK activator.
• O-304 is chemically distinct from OS-01.
• Research on Peptide 14 instead identified PP2A-related changes and did not establish a principal mechanism involving direct AMPK activation.
• Single-cell experiments did not demonstrate significant changes in apoptosis- or autophagy-related gene expression attributable to OS-01 under the reported conditions.
• Claims that OS-01 reliably stimulates mitophagy, mitochondrial biogenesis, muscle glucose uptake, or systemic fat oxidation remain unsupported.

12. The Proposed Bone-Regeneration Mechanism

• Bone remodeling involves coordinated activity of osteoblasts, osteoclasts, and osteocytes.
• Wnt/beta-catenin signaling, sclerostin, bone morphogenetic proteins, RUNX2, and Osterix participate in normal bone biology.
• These pathways are relevant to osteoporosis research generally.
• However, no independently verified OS-01-specific study establishes stimulation of these pathways, increased bone mineral density, or fracture healing.
• Research on other AMPK activators, sclerostin inhibitors, or bone-regenerative peptides cannot be attributed to OS-01.

The Key Difference: OS-01 is best characterized as a topical senomorphic research peptide with PP2A-associated cellular effects. The evidence does not support describing it as an injectable AMPK activator or established bone-building treatment.

Researchers are interested in OS-01 because it provides an approach to studying skin aging through cellular senescence rather than focusing only on surface hydration, pigment, or exfoliation.

• Cellular Senescence: Laboratory experiments demonstrate changes in senescence-associated cell populations and molecular markers.
• Senomorphic Therapy: Investigates the modification of cellular behavior without deliberately eliminating senescent cells.
• PP2A Signaling: Provides a potential connection between cellular phosphatase pathways, cell-cycle control, and senescence progression.
• Skin Barrier Repair: Controlled topical trials have reported improvements in selected TEWL and hydration measurements.
• Wrinkles and Skin Texture: Small human studies suggest cosmetic improvements over approximately twelve weeks.
• Inflammatory Signaling: Laboratory and preliminary human research suggests changes in SASP and circulating cytokine biomarkers.
• Biological-Age Measurements: Ex-vivo skin studies demonstrated changes in DNA-methylation age estimates.
• Extracellular Matrix: Changes in collagen-related and hyaluronic-acid-related gene expression provide a rationale for further structural skin research.
• Periorbital Aging: An eye-area formulation has been investigated for hydration, elasticity, firmness, wrinkles, and puffiness.
• Scalp Health: Commercial studies have examined a multi-ingredient scalp formulation containing OS-01, although peptide-specific hair-growth efficacy remains uncertain.
• Skin and Systemic Health: Exploratory studies investigate whether improved skin barrier function correlates with lower circulating inflammatory markers.
• Topical Delivery: Research examines whether peptide activity can be achieved locally without substantial measurable systemic exposure.

Research Limitation: OS-01 has a legitimate but early clinical research foundation. The strongest evidence concerns topical skin outcomes. Claims involving systemic rejuvenation, bone formation, muscle metabolism, or extended lifespan require separate studies.

OS-01 has demonstrated promising effects in laboratory skin models and selected human topical clinical studies. Its strongest evidence concerns skin-barrier function, moisture retention, and cosmetic measurements. Broader anti-aging and longevity outcomes remain unproven.

Selected Research Findings

2023 Cellular Senescence Research: Researchers identified Peptide 14 following screening of approximately one thousand peptides. They investigated human dermal fibroblasts affected by chronological aging, ultraviolet exposure, experimentally induced damage, and Hutchinson-Gilford Progeria Syndrome-related changes. Treatment reduced selected senescence markers without the substantial cell-death response expected from a senolytic compound.

2023 Experimental Skin Age Finding: Five days of exposure in excised human skin samples produced an average reduction of approximately 2.6 years in a DNA-methylation age estimate. This finding is scientifically interesting but does not show that applying a cosmetic product reverses a person's aging process by that amount.

2024 Randomized Facial Trial: A double-blind split-face study involved 22 participants using an OS-01-containing formulation on one side and the same vehicle without the peptide on the other side for twelve weeks. The peptide-treated side demonstrated superior changes in TEWL and selected measurements of wrinkle appearance and skin texture. The controlled design supports a peptide-related contribution, although the sample was small.

2025 Periorbital Study: Twenty-two participants aged 47–65 applied a multi-ingredient OS-01 eye-area product twice daily for twelve weeks. Compared with baseline, TEWL decreased 17.33%, hydration increased 32.49%, elasticity improved 25.58%, and firmness improved 10.19%. Expert assessments also reported changes in fine lines, wrinkles, puffiness, and dark circles.

Periorbital Study Limitation: The eye-area study did not include a simultaneous blinded comparison product. It therefore cannot establish how much of the observed improvement was caused specifically by OS-01 rather than moisturizers, other ingredients, or changes over time.

2025 Older-Adult Clinical Trial: A randomized, double-blind investigation enrolled 60 women aged 60–90 for twelve weeks, comparing an OS-01-containing topical product with another commercial moisturizer. The OS-01 group demonstrated improvements from baseline in TEWL and hydration.

Important Comparator Detail: The control moisturizer also substantially improved skin barrier function. Between-group statistical superiority was not established for every outcome. For example, forearm TEWL improved approximately 41.5% with OS-01 and 40.0% with control, without a significant difference between groups.

Upper-Arm Hydration: Hydration improved approximately 38.4% in the OS-01 group versus 7.2% in the comparator group, with a statistically significant between-group difference for this specific measurement.

Skin Appearance: Approximately 70% of participants in the OS-01 group reported improved general skin appearance versus 42% in the comparison group. Self-reported results are useful but are not a substitute for blinded objective measurements.

Circulating Inflammation: The 2025 study reported reductions in selected circulating cytokines, including IL-8 and IL-10, in the OS-01 group. Some inflammatory cytokines increased in the control group. These observations are preliminary and do not demonstrate prevention of systemic disease.

Systemic Biological-Age Claim: The study explored GlycanAge, which estimates aspects of immune-related biological age from immunoglobulin G glycosylation. The OS-01 group showed a more favorable trend than the control group, but this exploratory result does not establish reduced mortality, longer lifespan, or generalized whole-body rejuvenation.

Hair and Scalp Research: The manufacturer has reported improvements in hair-density and thickness measurements in users of a multi-ingredient OS-01 scalp serum. However, the promoted study also incorporated dermarolling, and the publicly available information does not establish an independent peptide-specific effect equivalent to established hair-loss treatments.

Bone Mineral Density and Osteoporosis: No identifiable controlled human trial demonstrates improved DEXA bone density, fewer fractures, or increased osteoblast activity from OS-01. Bone-related pathways proposed in general research should not be presented as established effects of this peptide.

Systemic Longevity: Neither the experimental molecular-age findings nor the small topical trials demonstrate longer life, reduced age-related disease incidence, or durable systemic rejuvenation.

Research Perspective: The strongest evidence supports further investigation of OS-01-containing topical products for skin barrier and cosmetic outcomes. Broader longevity and systemic-regeneration claims remain speculative.

OS-01 has been studied primarily through direct exposure of human skin cells, ex-vivo skin tissues, and finished topical skincare formulations. No published clinical trial establishes a safe or effective subcutaneous, intramuscular, or intravenous dose for OS-01. Commercial skincare instructions should not be confused with unvalidated research-market injection protocols.

Published Research and Reported Administration Amounts

Topical Research

• Experimental Concentration: A 2023 study optimized a formulation containing 0.01% Peptide 14 for ex-vivo skin testing.
• Cell Culture: Concentrations in micromolar units are used to study cellular responses directly and should not be converted into systemic treatment recommendations.
• Human Facial Research: Controlled clinical studies evaluated finished topical formulations applied twice daily over twelve weeks.
• Eye-Area Research: The published 2025 periorbital study used a multi-ingredient OS-01 eye cream twice daily.
• Body Application: The 2025 study of older adults used a commercial body formulation twice daily for twelve weeks.
• Commercial Concentration: The exact active-peptide concentration of every retail product is not independently established by its ingredient label.

Practical Distinction: Pure Peptide Versus Finished Formulation

• A finished cosmetic formula includes carriers, humectants, preservatives, and other ingredients that may affect skin penetration, stability, and tolerability.
• The clinical outcomes obtained with a finished moisturizer cannot be assumed to apply to isolated research-grade OS-01 powder.
• Adding raw peptide to an unrelated lotion does not reproduce a validated formulation.
• Skin penetration and biological activity depend on formulation chemistry, peptide stability, and skin-barrier condition.

Systemic and Injectable Administration

• Subcutaneous: No controlled human pharmacokinetic or dose-finding study establishes this route for OS-01.
• Intramuscular: No validated human administration regimen exists.
• Intravenous: No established pharmaceutical formulation or clinical regimen exists.
• Bone-Health Amounts: Weight-based doses sometimes promoted for bone building are not substantiated by identifiable OS-01-specific clinical data.
• Mechanistic Limitation: Published topical skin findings do not establish the effects of systemic injection on osteoblasts, sclerostin, bone mineral density, or fracture repair.
• Product Identity: Research-market material labeled OS-01 must not be assumed to contain the OneSkin peptide without independent chemical confirmation.

Reconstitution and Storage

• No approved injectable formulation or validated bacteriostatic-water reconstitution procedure exists for OS-01.
• There are no established stability data supporting a universal concentration, refrigeration schedule, or 28-day post-mixing expiration for research-market preparations.
• Commercial topical products should be stored according to their specific packaging instructions.
• Raw peptide stability depends on chemical identity, moisture, pH, oxygen, light, temperature, and excipients.
• Visual clarity or a laboratory purity certificate does not establish sterility, endotoxin safety, or suitability for injection.

Research Perspective: Published human OS-01 research supports evaluation of finished topical formulations, generally over twelve weeks. There is no scientifically validated human dose, injection schedule, or formulation for systemic longevity or bone-building treatment.

No validated long-term treatment cycle or washout period exists for OS-01. Human studies of topical formulations have generally evaluated twelve weeks of use, while cell and ex-vivo research has examined much shorter laboratory exposure periods.

• Cell-Culture Research: Experimental exposure commonly ranged from approximately 24–48 hours to several days, depending on the assay.
• Ex-Vivo Skin Biological Age: Five-day experimental exposure was used in the study reporting changes in DNA-methylation age.
• 2024 Facial Trial: Evaluated twelve weeks of twice-daily topical use.
• 2025 Periorbital Trial: Evaluated twice-daily use for twelve weeks.
• 2025 Older-Adult Trial: Evaluated twice-daily body application for twelve weeks.
• Early Cosmetic Assessments: Some studies observed changes after approximately four weeks.
• Commercial Maintenance: Ongoing daily skincare use is commonly suggested by manufacturers, but the optimal long-term frequency has not been established by controlled trials.
• Community Systemic Cycles: Four to six months of injections followed by two to three months without administration are sometimes promoted.
• Community Continuous Injections: Indefinite systemic administration is occasionally proposed without supporting human safety or efficacy data.
• Long-Term Clinical Outcomes: No large trial establishes durable skin-age reduction, lower disease risk, or improved lifespan from long-term OS-01 use.

Topical Maintenance: Improvement in skin hydration or TEWL during twelve weeks does not establish how long changes persist after stopping treatment.

Biological Age: An experimental reduction in a DNA-methylation age estimate over five days does not establish a need for a five-day, twelve-week, or six-month biological-age treatment cycle.

Injectable Cycling: No research demonstrates that alternating four to six months on treatment with several months off improves bone formation or prevents toxicity.

Research Perspective: Twelve weeks is the most relevant published human observation period. No validated systemic OS-01 cycle, washout interval, or long-term injectable maintenance protocol exists.

OS-01 is generally delivered in finished cosmetic formulations containing several established skincare ingredients. These ingredients may provide complementary effects on hydration, barrier maintenance, and skin appearance. However, improvements measured with multi-ingredient products do not establish direct pharmacological synergy between OS-01 and every other component.

Skincare Formulations: OneSkin products typically contain additional moisturizers, emollients, humectants, and other active ingredients. The effects of finished formulas may reflect multiple ingredients.

Retinol Comparison: A 2023 laboratory study compared OS-01 and retinol in ex-vivo skin models. These results do not establish clinical superiority of OS-01 over prescription retinoids or demonstrate that combining the two produces greater benefit.

Senolytic Combinations: OS-01 is investigated as a senomorphic candidate. No human trials establish improved outcomes from combining it with experimental senolytic drugs or peptides.

Bone-Health Combinations: Exercise, sufficient protein, calcium adequacy, and vitamin D sufficiency are important for bone health generally. However, no OS-01 study establishes that combining these factors with injections increases bone mineral density.

Research Perspective: Established skincare practices and finished topical formulations have a clearer evidence base than experimental peptide combinations. No clinical study validates OS-01 stacking for whole-body longevity, systemic inflammation reduction, or osteoporosis treatment.

OS-01 has a limited human topical safety database. Available studies generally report acceptable short-term tolerability, but skin reactions occurred in some participants. Systemic injectable safety has not been established.

2025 Older-Adult Trial — Important Adverse Events: Of thirty women assigned to the OS-01-containing body formulation, three discontinued following moderate skin reactions including persistent rash, pimples, or dry patches. The investigators indicated that reactions might have been associated with the skincare product or with the cleanser used during the study.

2025 Periorbital Study: The published study of twenty-two participants reported no adverse events and no participant withdrawals. Its sample size and duration were too limited to identify uncommon reactions or establish long-term safety.

2024 Controlled Facial Study: The split-face trial provides preliminary short-term tolerability information under controlled topical conditions but does not establish safety for every cosmetic formulation or skin condition.

Manufacturer-Associated Research: Several OS-01 clinical investigators are founders, employees, advisers, or patent inventors associated with the commercial product. Such relationships do not invalidate the findings, but independent replication is important.

Systemic Exposure: The 2025 study did not detect OS-01 in plasma at the measured time points. This does not establish that injecting the peptide would be safe or that every topical preparation has identical absorption.

Senescence Pathways: Cellular senescence has both beneficial and harmful physiological roles. Systemically changing these pathways without sufficient evidence raises unresolved questions about wound healing, tissue maintenance, and cancer biology.

Research Perspective: Short-term topical tolerability appears encouraging but is not risk-free. No clinically validated safety profile exists for injectable OS-01.

OS-01 is a cosmetic research peptide without an FDA-approved therapeutic indication. Formal drug contraindications have not been established, and the available human safety evidence is limited primarily to topical application in relatively small clinical studies.

• Known Ingredient Allergy: Avoid exposure to products containing ingredients that have previously caused allergic or severe skin reactions.
• Active Contact Dermatitis: Products may worsen irritation or complicate identification of the underlying trigger.
• Severely Compromised Skin: Absorption and local tolerability may differ substantially when the protective skin barrier is disrupted.
• Open Wounds: Cosmetic products should not be assumed suitable for application to deep or infected wounds.
• Recent Procedures: Skin affected by laser resurfacing, chemical peels, or microneedling may respond differently to concentrated topical ingredients.
• Eye Exposure: Only appropriately formulated products should be used near the eyes.
• Pregnancy and Breastfeeding: Adequate safety data for concentrated or systemic OS-01 exposure are unavailable.
• Children and Adolescents: Safety and effectiveness have not been established for experimental anti-aging treatment in these populations.
• Active Cancer: OS-01-related cellular signaling has not been adequately studied in people with malignancy.
• History of Skin Cancer: Experimental effects on cell-cycle and DNA-repair pathways do not establish prevention of skin cancer or safety during cancer treatment.
• Autoimmune or Inflammatory Skin Disease: Disease-specific benefits have not been established through adequately controlled OS-01 trials.
• Immunocompromised Individuals: No clinical trial establishes that OS-01 prevents infection or restores impaired skin immunity.
• Chronic Skin Ulcers: Improvements in cosmetic barrier measurements do not establish treatment effectiveness for diabetic, pressure-related, or vascular ulcers.
• Osteoporosis: No verified clinical evidence supports OS-01 as a treatment for low bone density.
• Recent Fracture: Experimental systemic treatment should not replace evaluation and evidence-based fracture management.
• Concurrent Experimental Peptides: Interactions and combined systemic safety have not been established.
• Unregulated Injectable Products: Raw peptide identity, stability, sterility, endotoxin levels, and systemic toxicity may be unknown.

U.S. Regulatory Status: OS-01 is marketed in cosmetic skincare formulations, but it is not an FDA-approved drug for skin disease, systemic rejuvenation, osteoporosis, fracture healing, or longevity.

Cosmetic Versus Drug Claims: Claims concerning moisturization, skin appearance, and cosmetic barrier support are distinct from claims that a product treats disease, rebuilds internal organs, or prevents biological aging.

Compound Identity: OS-01 should not be confused with O-304/ATX-304, a different small molecule investigated for AMPK activation. Their chemical identities, experimental mechanisms, and dosing information are not interchangeable.

Bone Health: Wnt signaling, sclerostin, and BMP pathways are important in skeletal biology, but these mechanisms have not been verified as therapeutic effects of OS-01. The absence of such evidence means that experimental weight-based injection claims should not be interpreted as validated protocols.

Long-Term Safety: The biological consequences of prolonged systemic manipulation of senescence-associated signaling are not established, including possible implications for wound healing, cellular proliferation, and cancer-related pathways.

Medical Consideration: Persistent skin inflammation, unexplained rashes, impaired wound healing, suspicious skin lesions, hair loss, or suspected osteoporosis require appropriate clinical evaluation rather than reliance on an unapproved experimental treatment.

OS-01 research has evaluated skin-barrier function, hydration, elasticity, wrinkle appearance, senescence-associated biomarkers, and selected circulating inflammatory measurements. The strongest human outcomes involve skin measurements rather than systemic disease or bone metabolism.

TEWL Consideration: Lower TEWL can indicate better epidermal barrier function. However, hydration and TEWL may improve with conventional moisturizers, so controlled comparisons are important.

Senescence Biomarkers: No single molecular marker definitively establishes whether a cell is senescent. Research typically evaluates several related markers together.

DNA-Methylation Age: Molecular-age estimates are computational biomarkers. A lower estimated age after experimental treatment does not independently establish increased lifespan or durable health benefits.

GlycanAge: Changes in IgG glycosylation are associated with inflammation-related physiology, but no validated threshold demonstrates that topical OS-01 slows systemic aging.

Inflammatory Cytokines: Cytokines vary with infection, stress, medical conditions, sampling, and normal immune activity. Lower values are not universally better, and changes in individual cytokines are not proof of whole-body rejuvenation.

Plasma Peptide Measurements: Nondetection at a study's sampling points should be interpreted according to assay sensitivity and sampling design.

Bone Biomarkers: DEXA, P1NP, alkaline phosphatase, and CTX are useful in appropriate bone-health research, but no published study validates them for determining the effectiveness of OS-01 injections.

Important Limitation: No biomarker panel, biological-age target, or measurement interval has been validated to establish the effectiveness or safety of systemic OS-01 treatment.